EGFR and Hyperglycemia: Hyperglycemia-mediated decrease in FOXO3A phosphorylation and increased total FOXO3A levels could be reversed upon lapatinib treatment (a dual inhibitor of EGFR and ErbB2 receptors) (Benter et al., 2015).